ProPhase Labs, Inc. filings document material events, capital-structure changes, listing status, and operating updates for an OTC-traded life sciences, diagnostics, genomics and consumer health company. Form 8-K disclosures cover the BE-Smart™ esophageal cancer risk stratification test, Crown Medical Collections activity involving legacy COVID-19 testing receivables, shareholder communications, and updates on underlying assets.
The company’s SEC record also includes disclosures on common stock listed for OTC trading under PRPH, a Nasdaq Form 25 delisting notice, a reverse stock split, convertible debt conversions, an equity line stock purchase agreement, related warrant issuance, and unregistered equity sales. Periodic-reporting records include an NT 10-K notice tied to the year-end financial reporting process.
ProPhase Labs (Nasdaq: PRPH) filed an 8-K (Item 3.01 & 7.01) disclosing it remains non-compliant with Nasdaq Listing Rule 5550(a)(2) after its shares closed below $1.00 for 30 consecutive trading days. Nasdaq granted a second 180-day extension, moving the cure deadline to December 22 2025. To regain compliance, PRPH must record a closing bid price of at least $1.00 for 10 consecutive business days and receive staff confirmation. Failure to do so will trigger a delisting notice and trading suspension, with only a non-staying appeal available. The company states it is otherwise compliant with all other listing standards and is “actively monitoring” its stock price while evaluating options. A related press release was furnished as Exhibit 99.1.
ProPhase Labs (Nasdaq:PRPH) filed a routine Form 8-K disclosing the appointment of Carolina Abenante, Esq. as an independent director effective June 20, 2025. She immediately joins the Nominating & Corporate Governance Committee and becomes Chair of the Compensation Committee; the Board also intends to add her to the Audit Committee after July 19, 2025, pending shareholder approval. Abenante, 55, is considered independent and financially literate under Nasdaq and SEC rules and brings tax, finance and legal expertise from prior executive roles at NYIAX and other AdTech firms. Director compensation matches existing non-employee terms: $48,000 annual cash retainer plus participation in the Director’s Equity Plan. The company reported no related-party transactions or family relationships.
ProPhase Labs (NASDAQ:PRPH) filed its 2025 Definitive Proxy Statement for the Annual Meeting of Stockholders scheduled for July 18, 2025 at 4:00 p.m. ET in Lynbrook, NY.
Stockholders will vote on four routine items:
- Proposal 1: Elect four director nominees to serve until the 2026 meeting.
- Proposal 2: Ratify Fruci & Associates II, PLLC as independent auditor for fiscal 2025.
- Proposal 3: Advisory Say-on-Pay vote on 2024 executive compensation.
- Proposal 4: Advisory vote on the frequency of future Say-on-Pay votes.
The record date is June 20, 2025; only shareholders of record at that close of business may vote. The proxy materials and the company’s 2024 Form 10-K are available at www.proxyvote.com. Holders may vote by proxy in advance or in person. No contested matters, major transactions, or material changes are disclosed.